Acetylcholinesterase inhibitor treatment for myasthenia gravis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Mehndiratta, Man Mohan ^a   Pandey, Sanjay ^a   Kuntzer, Thierry ^b  

^a G B PANT HOSPITAL   (India)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; NEOSTIGMINE;

ADVERSE EVENT; CLINICAL FEATURE; DATA BASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; MUSCLE FUNCTION; MYASTHENIA GRAVIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; INTRANASAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; CHOLINESTERASE INHIBITORS; HUMANS; MYASTHENIA GRAVIS; NEOSTIGMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921968588     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006986.pub3     Document Type: Review

References (52)

1. Badrising U, Brandenburg H, van Hilten J, Brietl P, Wintzen A. Intranasal neostigmine as add-on therapy in myasthenia gravis. Journal of Neurology 1996;243 Suppl:59.
2. Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. Journal of Neurology 1997;244(2):112-8.
3. Hatanaka YH. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 2005;65(9):1508-9.
4. Schwarz H. Mestinon (pyridostigmine bromide) in myasthenia gravis. Canadian Medical Association Journal 1956 Jul 15;75(2):98-100.
5. Seto M, Motomura M, Takeo G, Yoshimura T, Tsujihata M, Nagataki S. Treatment of myasthenia gravis: a comparison of the natural course and current therapies. Tohoku Journal of Experimental Medicine 1993;169:77-86.
6. Slesak G, Melms A, Gerneth F, Sommer N, Weissert R, Dichgans J. Late-onset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60. Annals of the New York Academy of Sciences 1998 May 13;841:777-80.
7. Zhou SZ, Li WH, Sun DK. Myasthenia gravis in children: clinical study of 77 patients. [Chinese]. Zhonghua Erke Zazhi 2004;42:256-9.
8. Bedlack RS, Simel DL, Bosworth G, Samsa B, Tucker-Lipscomb, Sanders DB. Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity. Neurology 2005;64(11):1968-70.
9. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscular Disorders 2006;16:459-67.
10. Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD005081.pub2]
11. Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008 Oct 21;71(17):1335-41.
12. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. Journal of Clinical Investigation 2006 Nov;116(11):2843-54.
13. Daroff RB. The office Tensilon test for ocular myasthenia gravis. Archives of Neurology 1986 Aug;43(8):843-4.
14. Drachman DB, Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003;61(12):1652-61.
15. Drachman DB. Myasthenia gravis. The New England Journal of Medicine 1994 Jun 23;330(25):1797-810.
16. Dukes MNG, Aronson JK (editors). Meyler's Side Effects of Drugs. 15th Edition. Oxford: Elsevier, 2006.
17. Engel AG, Lambert EH, Santa T. Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure. Neurology 1973 Dec;23(12):1273-81.
18. Engel AG, Hohfeld R. Acquired autoimmune myasthenia gravis. In: Engel AG, Armstrong CF editor(s). Myology. 3rd Edition. New York: McGraw Hill, 2004:1755-90.
19. Engel AG. The therapy of congenital myasthenic syndromes. Neurotherapeutics 2007 April;4(2):252-7.
20. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD002275]
21. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD002277.pub3]
22. Gehi A, Benatar M, Langberg J. Treatment of pyridostigmine-induced AV block with hyoscyamine in a patient with myasthenia gravis. Cardiovascular Electrophysiology 2008 Feb;19(2):214-6.
23. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.
24. Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Annals of the New York Academy of Sciences 1981;377:652-69.
25. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005224.pub2]
26. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. [updated September 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
27. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
28. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al.Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000 Jul 12;55(1):16-23.
29. Munsat TL. Anticholinesterase abuse in myasthenia gravis. Journal of the Neurological Sciences 1984 Apr;64(1):5-10.
30. Newsom-Davis J. The emerging diversity of neuromuscular junction disorders. Acta Myologica 2007 Jul;26(1):5-10.
31. Nicholson GA, McLeod JG, Griffiths LR. Comparison of diagnostic tests in myasthenia gravis. Clinical and Experimental Neurology 1983;19:45-9.
32. Oosterhuis HJ. Observations of the natural history of myasthenia gravis and the effect of thymectomy. Annals of the New York Academy of Sciences 1981;377:678-90.
33. Oosterhuis HJ. Long-term effects of treatment in 374 patients with myasthenia gravis. Monographs in Allergy 1988;25:75-85.
34. Osserman KE, Kaplan LI. Rapid diagnostic test for myasthenia gravis: increased muscle strength, without fasciculations, after intravenous administration of edrophonium (tensilon) chloride. Journal of the American Medical Association 1952 Sep 27;150(4):265-8.
35. Punga AR, Sawada M, Stålberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 2008;37:300-7.
36. Punga AR, Stalberg E. Acetylcholinesterase inhibitors in MG: to be or not to be. Muscle & Nerve 2009;39:724-8.
37. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003;61(12):1652-61.
38. Rowland LP. Controversies about the treatment of myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry 1980 Jul;43(7):644-59.
39. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003 Jun 24;60(12):1978-80.
40. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002828.pub2]
41. Shapira M, Tur-Kaspa I, Bosgraaf L, Livni N, Grant AD, Grisaru D, et al.Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-80.
42. Sieb JP, Köhler W. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial. Clinical Neurology and Neurosurgery 2010;112(9):781-4.
43. Simpson JF, Westerberg MR, Magee KR. Myasthenia gravis. An analysis of 295 cases. Acta Neurologica Scandinavica 1966;42 Suppl 23:1-27.
44. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Hart IK, Harms L, et al.Guidelines for the treatment of autoimmune neuromuscular transmission disorders. European Journal of Neurology 2006;13(7):691-9.
45. Taylor P. Chapter 8: Anticholinesterase agents. In: Joel G. Hardman editor(s). The Pharmacological Basis of Therapeutics. 9th Edition. New York: McGraw Hill, 1996:161-76.
46. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. Journal of Neurology, Neurosurgery and Psychiatry 1985;48(12):1246-52.
47. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357(9274):2122-8.
48. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurology 2003;2(2):99-106.
49. Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 1934;2:1198-9.
50. Walker MB. Procedings of the Royal Society of Medicine. 1935; Vol. 28:759-60.
51. Mehndiratta MM, Kuntzer T, Pandey S. Anticholinesterase treatment for myasthenia gravis. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD006986]
52. Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD006986.pub2]